884340-46-9 Usage
Description
(4-Chloro-3-nitro-pyridin-2-yl)-methyl-amine is a chemical compound characterized by the molecular formula C6H6ClN3O2. It is a nitro-substituted pyridine derivative featuring a chloro group attached to the second carbon of the pyridine ring. (4-Chloro-3-nitro-pyridin-2-yl)-methyl-amine holds potential for various applications due to its unique structural properties.
Uses
Used in Pharmaceutical Industry:
(4-Chloro-3-nitro-pyridin-2-yl)-methyl-amine is used as a building block for the synthesis of pharmaceutical drugs. Its unique structure allows it to be a valuable intermediate in the development of new medications with potential therapeutic applications.
Used in Agricultural Industry:
In the agricultural sector, (4-Chloro-3-nitro-pyridin-2-yl)-methyl-amine is utilized as an intermediate in the creation of agrochemicals. Its properties make it a promising candidate for the development of compounds that can be used in pest control or as additives to enhance crop yield and quality.
Given the compound's potential applications, further research and development are necessary to fully understand its properties and optimize its use in both the pharmaceutical and agricultural industries.
Check Digit Verification of cas no
The CAS Registry Mumber 884340-46-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,4,3,4 and 0 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 884340-46:
(8*8)+(7*8)+(6*4)+(5*3)+(4*4)+(3*0)+(2*4)+(1*6)=189
189 % 10 = 9
So 884340-46-9 is a valid CAS Registry Number.
884340-46-9Relevant articles and documents
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF)
Niculescu-Duvaz, Dan,Gaulon, Catherine,Dijkstra, Harmen P.,Niculescu-Duvaz, Ion,Zambon, Alfonso,Menard, Delphine,Suijkerbuijk, Bart M. J. M.,Nourry, Arnaud,Davies, Lawrence,Manne, Helen,Friedlos, Frank,Ogilvie, Lesley,Hedley, Douglas,Whittaker, Steven,Kirk, Ruth,Gill, Adrian,Taylor, Richard D.,Raynaud, Florence I.,Moreno-Farre, Javier,Marais, Richard,Springer, Caroline J.
supporting information; experimental part, p. 2255 - 2264 (2010/01/15)
BRAF is a serine/threonine kinase that is mutated in a range of cancers, including 50-70% of melanomas, and has been validated as a therapeutic target. We have designed and synthesized mutant BRAF inhibitors containing pyridoimidazolone as a new hinge-binding scaffold. Compounds have been obtained which have low nanomolar potency for mutant BRAF (12 nM for compound 5i) and low micromolar cellular potency against a mutant BRAF melanoma cell line, WM266.4. The series benefits from very low metabolism, and pharmacokinetics (PK) that can be modulated by methylation of the NH groups of the imidazolone, resulting in compounds with fewer H-donors and a better PK profile. These compounds have great potential in the treatment of mutant BRAF melanomas.
